Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01780662|
Recruitment Status : Active, not recruiting
First Posted : January 31, 2013
Last Update Posted : June 26, 2018
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Adult Hodgkin Lymphoma Recurrent Childhood Hodgkin Lymphoma Refractory Childhood Hodgkin Lymphoma||Drug: Brentuximab Vedotin Drug: Gemcitabine Hydrochloride||Phase 1 Phase 2|
I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of brentuximab vedotin in combination with gemcitabine administered every three weeks to children with relapsed or primary refractory Hodgkin lymphoma (HL).
II. To define and describe the toxicities of brentuximab vedotin in combination with gemcitabine administered on this schedule.
III. To determine the complete response (CR) rate after treatment with four cycles of gemcitabine with brentuximab vedotin among patients with relapsed or refractory HL.
I. To preliminarily define the antitumor activity of brentuximab vedotin in combination with gemcitabine within the confines of a Phase 1 study.
II. To describe the overall response rate (ORR) after 4 cycles of therapy among patients with relapsed or refractory HL.
III. To describe the proportion of patients with HL able to mobilize an adequate yield of cluster of differentiation (CD) 34+ stem cells after gemcitabine with brentuximab vedotin.
IV. To describe the relationship between disease response among patients with HL and changes in thymus and activation-regulated chemokine (TARC) during treatment, and to determine if specific micro ribonucleic acid (miRNA) profiles correlate with response to treatment.
V. To describe the frequency of the Fc gamma receptor IIIa (FcγRIIIa)-158 valine (V)/phenylalanine (F) polymorphism among patients who experience pulmonary toxicity on this protocol.
OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin followed by a phase II study. (Phase I completed as of amendment 4)
Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.
After completion of study treatment, patients are followed up at 3, 6, 9, 12, 18, 24, 36, 48, and 60 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||72 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1/2 Study of Brentuximab Vedotin (SGN35) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma|
|Actual Study Start Date :||January 31, 2013|
|Actual Primary Completion Date :||September 30, 2017|
Experimental: Treatment (brentuximab vedotin, gemcitabine hydrochloride)
Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.
Drug: Brentuximab Vedotin
Drug: Gemcitabine Hydrochloride
- MTD of brentuximab vedotin in combination with gemcitabine hydrochloride defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity (DLT) as assessed by National Cancer Institute (NCI) CTCAE v 4.0 (Part A) [ Time Frame: Up to 21 days ]
- Adverse events graded according to NCI CTCAE v4.0 (Part A) [ Time Frame: Up to 13 months ]
- Complete response (CR) rate [ Time Frame: At 12 weeks ]
- Describe disease response [ Time Frame: Up to 12 weeks ]
- Overall response rate (ORR) after four cycles of therapy [ Time Frame: At 12 weeks ]
- Describe proportion of Hodgkin Lymphoma (HL) patients with successful CD34+ stem cells collection after gemcitabine with brentuximab vedotin [ Time Frame: Up to 5 years ]Successful stem cell collection was defined as a collection of more than 2x10^6 CD34 positive cells.
- Plasma level of thymus and activation-regulated chemokine (TARC) [ Time Frame: Up to day 21 of course 16 ]Summarized by median, and range of TARC levels at baseline and at cycle 2.
- Determine if micro ribonucleic acid (miRNA) profiles correlate with response to treatment [ Time Frame: Up to day 1 of course 16 ]The association between response and miRNA profile will be explored by comparing the specific miRNA level or change over time between patients with CR versus < CR.
- Frequency of the FcyRIIIa-158 V/F polymorphism [ Time Frame: Up to day 1 of course 16 ]Among patients who experience any pulmonary toxicity, the frequency of the FcγRIIIa-158 V/F polymorphism will be described.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01780662
Show 116 Study Locations
|Principal Investigator:||Peter Cole||Children's Oncology Group|